News und Analysen
Intrexon Depended on 1 Customer for 58% of First-Half 2017 Revenue Growth
The single biggest problem facing engineered biology conglomerate Intrexon (NYSE: XON) heading into the second quarter of 2017 was its dependency on small- and micro-cap companies for a significant
2 Marijuana Stocks That Turned $10,000 Into $125,000 and $300,000, Respectively
When it comes to top-performing industries, you'd have a tough time surpassing the returns of marijuana stocks. Of the 13 marijuana stocks with a market cap in excess of $200 million, over half have
Better Buy: Exact Sciences Corporation vs. Opko Health
"It was the best of times, it was the worst of times..."Charles Dickens wasn't referring to Exact Sciences (NASDAQ: EXAS) and Opko Health (NASDAQ: OPK) when he wrote those words, but they're certainly
Why Pan American Silver, Chefs' Warehouse, and Perrigo Jumped Today
Thursday was one of the worst sessions that the stock market has seen in several months, with major benchmarks falling 1% or more. Investors are growing increasingly nervous about the rising tensions
Here's Why Perrigo Company Rose as Much as 20.5% Today
Shares of Perrigo Company (NYSE: PRGO) rose over 20% this morning after the healthcare leader released second-quarter 2017 financial results and adjusted full-year 2017 guidance. While revenue slipped
3 High-Yield Healthcare Stocks
The healthcare sector is a natural hunting ground for income investors, since consumers demand access to high-quality healthcare products in good times and bad. That fact helps keep many healthcare
3 High-Yield Healthcare Stocks
The healthcare sector is a natural hunting ground for income investors, since consumers demand access to high-quality healthcare products in good times and bad. That fact helps keep many healthcare
Organovo Holdings Revenue Is Growing at a Snail's Pace Compared With Prior Quarters
It's been a crazy year for Organovo Holdings (NASDAQ: ONVO) so far. The 3D bioprinting company's former CEO abruptly left in April. Organovo disappointed investors with its fourth-quarter and
The Sole Reason Amicus Therapeutics, Inc. Exploded 29% Higher in July
Shares of Amicus Therapeutics (NASDAQ: FOLD), a biopharmaceutical company focused on the development rare-disease drugs, exploded higher by 29% during the month of July, according to data from S&P
Here's Why Surgery Partners Inc. Is Sinking Today
Shares of Surgery Partners Inc. (NASDAQ: SGRY), a provider of surgical care services, tanked 52% shortly after the opening bell this morning in response to an earnings miss on the top and bottom
The 1 Very Clear Reason Arena Pharmaceuticals, Inc. Skyrocketed 41% in July
Shares of Arena Pharmaceuticals (NASDAQ: ARNA), a biopharmaceutical company focused on the development of small-molecule drugs for the treatment of a variety of diseases, catapulted 41% during July
Here's Why Acadia Pharmaceuticals Inc. Is Soaring Today
In response to Acadia Pharmaceuticals (NASDAQ: ACAD) reporting blow-out earnings and sharing upbeat guidance, shares of the commercial-stage biopharma, which focuses on diseases of the central nervous
2 Reasons Behind Achillion Pharmaceuticals, Inc.'s 11% Tumble in July
Shares of Achillion Pharmaceuticals (NASDAQ: ACHN), a clinical-stage drug developer focused on small-molecule treatments for infectious diseases, such as hepatitis C, turned in a dismal July and sank
2 Reasons Behind Achillion Pharmaceuticals, Inc.'s 11% Tumble in July
Shares of Achillion Pharmaceuticals (NASDAQ: ACHN), a clinical-stage drug developer focused on small-molecule treatments for infectious diseases, such as hepatitis C, turned in a dismal July and sank
Why Achillion Pharmaceuticals Is Shooting 25% Higher Today
After the company updated investors on its second-quarter financials and the progress it's making in its clinical-stage drug pipeline, shares in Achillion Pharmaceuticals (NASDAQ: ACHN) are soaring
Why Achillion Pharmaceuticals Is Shooting 25% Higher Today
After the company updated investors on its second-quarter financials and the progress it's making in its clinical-stage drug pipeline, shares in Achillion Pharmaceuticals (NASDAQ: ACHN) are soaring
Here's Why NantKwest Inc. Tumbled 21.1% in July
Shares of NantKwest (NASDAQ: NK), a clinical-stage biotech company primarily focused on immunotherapy compounds that treat cancer, fell by 21% in July, according to S&P Global Market Intelligence. The
Exelixis, Inc. Continued Its Winning Ways and Rose 10% in July Thanks to These 3 Catalysts
Shares of Exelixis (NASDAQ: EXEL), a biotechnology company focused on the development of drugs to treat various types of cancer, moved steadily higher by a cool 10% in July, according to data from S&P
This Marijuana Stock Skyrocketed Last Week, While 3 Others Plunged
When it comes to the market's top-performing stocks, you'd have a hard time topping marijuana stocks over the trailing year. A majority of pot stocks over the past 12 months have at least doubled in
The 3 Best Buffett Stocks for Retirees
Quality and durability should be the two pillars of any retiree's stock portfolio. A company that has a long track record of success and a bright future thanks to durable competitive advantages is the
The 3 Best Buffett Stocks for Retirees
Quality and durability should be the two pillars of any retiree's stock portfolio. A company that has a long track record of success and a bright future thanks to durable competitive advantages is the
Is This Why bluebird bio Dipped 10.5% in July?
bluebird bio (NASDAQ: BLUE), a clinical-stage biotech focused on gene therapy, fell more than 10% in July, according to S&P Global Market Intelligence. However, there wasn't any news released during
Illumina Introduces a New Genomic Era
Illumina's (NASDAQ: ILMN) second-quarter earnings crushed expectations last week. Investors cheered the company's raised guidance, and the stock is up more than 15% since the report.Illumina's genomic
Illumina Introduces a New Genomic Era
Illumina's (NASDAQ: ILMN) second-quarter earnings crushed expectations last week. Investors cheered the company's raised guidance, and the stock is up more than 15% since the report.Illumina's genomic
Illumina Introduces a New Genomic Era
Illumina's (NASDAQ: ILMN) second-quarter earnings crushed expectations last week. Investors cheered the company's raised guidance, and the stock is up more than 15% since the report.Illumina's genomic